Atea Pharmaceuticals, Inc. (AVIR) Dividend History

Atea Pharmaceuticals, Inc. (AVIR) is a biotechnology company focused on developing innovative antiviral therapies for infectious diseases. The company leverages its proprietary research platform to discover and advance new treatments for viral illnesses, with an emphasis on respiratory viruses such as COVID-19. Atea collaborates with partners and clinical organizations to accelerate the development of its pipeline candidates.

225 Franklin Street, Boston, MA, 02110
Phone: 857-204-8109
Website: https://www.ateapharma.com

Dividend History

Atea Pharmaceuticals, Inc. currently does not pay dividends

Company News

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

Atea Pharmaceuticals announced that it will present data from a Phase 2 clinical study of its regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) at the EASL Congress 2025. The regimen has the potential to be a best-in-class treatment option with a short duration, low risk of drug interactions, and convenience.

GlobeNewswire Inc.
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Atea Pharmaceuticals has dosed the first patient in its Phase 3 trial evaluating a regimen of bemnifosbuvir and ruzasvir for the treatment of chronic hepatitis C virus (HCV). The regimen has the potential to be a best-in-class therapy with a short treatment duration, low risk of drug-drug interactions, and convenience.

GlobeNewswire Inc.
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Atea Pharmaceuticals has taken several actions to enhance shareholder value, including a strategic review, cost-cutting measures, and the appointment of a new independent director.

GlobeNewswire Inc.
Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, has received a notice from a shareholder group, Bradley L. Radoff, that he intends to nominate three director candidates for election to the Atea Board of Directors at the company's 2025 Annual Meeting of Stockholders. Atea's Board and management team will evaluate the director candidates and make a formal recommendation in the company's proxy statement.

GlobeNewswire Inc.
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Atea Pharmaceuticals presented preclinical data on its hepatitis C drug candidate bemnifosbuvir at the ICAR 2025 conference. The company is initiating a global Phase 3 program for the bemnifosbuvir and ruzasvir combination regimen to treat hepatitis C.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 17:49:55 UTC